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Abstract The role of the gut microbiota in health and
disease is becoming increasingly recognized. The micro-
biota–gut–brain axis is a bi-directional pathway between
the brain and the gastrointestinal system. The bacterial
commensals in our gut can signal to the brain through a
variety of mechanisms, which are slowly being resolved.
These include the vagus nerve, immune mediators and
microbial metabolites, which influence central processes
such as neurotransmission and behaviour. Dysregulation in
the composition of the gut microbiota has been identified in
several neuropsychiatric disorders, such as autism,
schizophrenia and depression. Moreover, preclinical stud-
ies suggest that they may be the driving force behind the
behavioural abnormalities observed in these conditions.
Understanding how bacterial commensals are involved in
regulating brain function may lead to novel strategies for
development of microbiota-based therapies for these neu-
ropsychiatric disorders.
Key Points
The gut microbiota regulate central nervous system
homeostasis through immune, vagal and metabolic
pathways.
Dysregulation of the gut microbiota has been
documented in several neuropsychiatric conditions,
such as depression and autism.
Preclinical and clinical evidence suggests that
psychobiotics display efficacy in alleviating the
behavioural symptoms of neuropsychiatric disorders.
1 Introduction
‘‘The Force is what gives a Jedi his power. It’s an
energy field created by all living things. It surrounds
us and penetrates us.’’ (Obi Wan Kenobi, Star Wars:
Episode IV—A New Hope)
The microbiota are not unlike the mystical Force seen in
the Star Wars movies. In these movies, individuals who
can sense the Force are said to contain a large number of
‘midi-chlorians’, which are ‘‘microscopic lifeforms that
live symbiotically inside the cells of all living things’’ (Qui
Gon Jinn, Star Wars: Episode I—The Phantom Menace.
Similarly, we share a symbiotic relationship with the bac-
terial microorganisms that live within us, with a large
population residing within our gastrointestinal system.
Recent advances in sequencing technology have revealed
that the microbiota in our gut comprise approximately 1800
different phyla and 40,000 bacterial species [1]. The main
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bacterial phyla in the gut include the Firmicutes (such as
Lactobacillus) and the Bacteroidetes (i.e. Bacteroides);
other phyla include Proteobacteria, Actinobacteria (i.e.
Bifidobacterium) and Cyanobacteria [2]. The gut micro-
biota, like the Force, give us power. These various species
of bacteria interact with the rest of the body through reg-
ulation of the immune system and secretion of factors such
as short-chain fatty acids (SCFAs), which influence phys-
iological processes throughout the body. Through a bi-di-
rectional communication network with the brain, called the
microbiota–gut–brain axis, the bacterial commensals help
to maintain homeostasis of the central nervous system
(CNS) and influence our behaviour and mood. In the Star
Wars movies, Jedi knights are known for their calm,
peaceful demeanour and positivity. Modulators of the
microbiota, such as prebiotics and probiotics, have been
shown to reduce levels of the stress hormone cortisol and
improve mood in healthy volunteers, making their beha-
viour more ‘Jedi-like’ [3]. Interestingly, there is consider-
able evidence to suggest a role for the gut microbiota in
neuropsychiatric conditions, such as depression, autism and
schizophrenia, which may be the driving force behind the
behavioural abnormalities observed in these disorders.
2 Communication Between the Gut Microbiota
and the Brain
‘‘I could show you the ways of the Force.’’ (Kylo
Ren, Star Wars: Episode VII—The Force Awakens)
The bacterial commensals in our gut communicate with
the CNS and regulate brain neurochemistry and behaviour
in a number of different ways, which are slowly being
resolved. These mechanisms include production of bacte-
rial metabolites and immune mediators, such as cytokines,
and signalling to the brain directly via the vagus nerve
[4–6] (see Fig. 1).
2.1 Immune Responses
The immune system acts as an important intermediary
between the gut microbiota and the brain [4]. The sig-
nalling mediators of the immune system—cytokines—can
signal to the brain from the periphery via the vagus nerve,
or they can access the brain directly via the circumven-
tricular organs (regions of the blood–brain barrier [BBB]
that are relatively permeable). Gram-negative bacteria can
stimulate production of pro-inflammatory cytokines, such
as interleukin (IL)-6 and IL-1b, through binding of the
lipopolysaccharide (LPS) component of their cell walls to
toll-like receptors (TLRs; i.e. TLR-4), which are expressed
upon monocytes, macrophages and microglia. In conditions
such as irritable bowel syndrome (IBS) and depression,
there is thought to be a breakdown in intestinal perme-
ability, which leads to translocation of bacteria from the
lumen of the gut to the systemic circulation, where they can
elicit an inflammatory response by stimulating TLR-4 on
circulating immune cells [7, 8]. The inflammatory response
in the gut can also signal to the brain via the vagus nerve.
For instance, intestinal inflammation in mice, triggered by
Campylobacter jejuni infection, was associated with
increased neuronal activation (represented by c-Fos
immunohistochemistry) in vagal sensory ganglia and in the
nucleus of the solitary tract (the primary afferent of the
vagus nerve), indicating that intestinal inflammation sig-
nals to the brain via this nerve [9]. VSL#3—a probiotic
composed of various Lactobacilli, Bifidobacteria and a
Streptococcus species—attenuated both sickness behaviour
and systemic inflammation induced by bile duct ligation
[10]. Studies such as these demonstrate that the gut
microbiota are capable of modulating the peripheral
inflammatory response, which can affect brain function and
behaviour.
2.2 The Vagus Nerve
The tenth (X) cranial nerve—the vagus nerve—plays a
crucial role in facilitating bi-directional communication
between the brain and the gut microbiota [11, 12]. The
vagus nerve represents the main afferent pathway from the
abdominal cavity to the brain, and there is sufficient evi-
dence to indicate that the gut microbiota are capable of
activating this pathway to mediate their behavioural and
physiological effects on the brain. For instance, the vagus
nerve is responsible for mediating the beneficial effects of
probiotics on physiological mechanisms such as wound
healing [13]. Lactobacillus reuteri was shown to enhance
wound healing in mice by increasing oxytocin release from
the hypothalamus, which was effectively blocked follow-
ing vagotomy [13]. The vagus nerve is also a crucial
component in mediating how alterations in the gut micro-
biota impact upon behaviour. For instance, transient inac-
tivation of the dorsal vagal complex was shown to
attenuate social isolation deficits, which were induced
following peripheral LPS administration [14]. Severing of
the vagus nerve also facilitated anxiolytic-like behaviour in
rats, which was accompanied by an attenuation in condi-
tioned fear [15]. Furthermore, the anxiogenic behaviour
induced by dextran sulfate sodium (DSS)–mediated colitis
was attenuated following vagotomy, indicating that the
vagus nerve is an intermediary in facilitating the detri-
mental behavioural effects of colonic inflammation.
Vagotomy also blocked the anxiolytic effect of Bifi-
dobacterium longum in step-down inhibitory avoidance
[16]. Similarly, the anxiolytic and antidepressant-like
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effects observed following Lactobacillus rhamnosus
ingestion were not observed in vagotimized mice [11].
Thus, the vagus nerve is also important in mediating the
beneficial behavioural effects of probiotics. However, it
must be considered that the vagus nerve is not the only
route through which the microbiota can influence beha-
viour. Bercik and colleagues [17] demonstrated that when
the composition of the gut microbiota in mice was tran-
siently altered following antimicrobial administration, the
anxiolytic effect of the antimicrobial treatment was inde-
pendent of the vagus nerve. This suggests that there are
other biological mechanisms at play, mediating the beha-
vioural effects of the gut microbiota.
2.3 Short-Chain Fatty Acids
Acetic acid, propionic acid and butyric acid are the main
SCFA metabolites produced by the bacterial commensals
in our gut. These SCFAs are inhibitors of histone
deacetylases [18] and can also elicit intracellular sig-
nalling by binding to their cognate G-protein coupled
receptors (e.g. free fatty acid receptors [FFARs]) to
Fig. 1 Key communication pathways of the microbiota–gut–brain
axis. There are numerous mechanisms through which the bacterial
commensals in our gut can signal to the brain. These include
activation of the vagus nerve, production of immune mediators and
microbial metabolites (i.e. short-chain fatty acids [SCFAs]), and
enteroendocrine cell signalling. Through these routes of communica-
tion, the microbiota–gut–brain axis controls central physiological
processes, such as neurotransmission, neurogenesis, neuroinflamma-
tion and neuroendocrine signalling. Dysregulation of the gut
microbiota subsequently leads to alterations in all of these central
processes. There have been numerous reports of alterations in the gut
microbiota in neuropsychiatric conditions, which may account for the
behavioural abnormalities that are characteristic of these conditions.
Normalizing the composition of the gut microbiota with use of
probiotics and prebiotics may represent a viable treatment option for
neuropsychiatric conditions. 5-HT serotonin, CCK cholecystokinin,
GABA c-aminobutyric acid, GLP glucagon-like peptide, IL inter-
leukin, PYY peptide YY, TNF tumour necrosis factor
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influence a range of physiological functions throughout
the body [19]. These SCFAs act as an intermediary
between the gut microbiota and the brain, and they rep-
resent an additional mechanism through which gut bac-
teria can influence brain physiology and behaviour.
Microbial-derived SCFAs are capable of signalling to the
brain indirectly via nerve activation to influence physi-
ology and behaviour. Propionic acid exerts beneficial
effects upon body weight control and glucose metabolism
by activating the FFAR3 receptor upon nerve fibres of the
portal vein [20]. On the other hand, SCFAs can affect
brain physiology and behaviour directly. Evidence sug-
gests that butyric acid and propionic acid are capable of
modulating neurotransmission [21–23]. Both butyric acid
and propionic acid have been shown to increase expres-
sion of tyrosine hydroxylase, the rate-limiting enzyme in
dopamine and noradrenaline synthesis [23]. These SCFAs
also attenuated expression of dopamine-b-hydroxylase,
the enzyme responsible for converting dopamine into
noradrenaline. Propionic acid also increased tryptophan
hydroxylase expression, which suggests that this SCFA is
also capable of modulating serotonergic neurotransmis-
sion [23]. Propionic acid has been shown to lower levels
of c-aminobutyric acid (GABA), the indoleamine sero-
tonin (5-hydroxytryptamine; 5-HT) and dopamine in vivo
[24]. These effects of SCFAs on brain physiology may
help to explain their effect upon behaviour, as butyric
acid has been shown to produce antidepressant-like
effects in preclinical tests, while neurotoxic or excessive
doses of propionic acid are associated with deficits in
cognition and sociability [25–28].
SCFAs are also capable of regulating glial homeostasis.
Pretreatment of primary microglial cultures with butyric
acid has been reported to protect against LPS-induced
inflammatory responses [29]. Moreover, long-term SCFA
treatment has been reported to reverse microglial imma-
turity and malformation observed in germ-free mice (mice
that had grown up without any exposure to microbes),
which was dependent upon activation of FFAR2 [30].
However, this effect of SCFAs upon microglial home-
ostasis is not as straightforward as it seems, as propionic
acid has been shown to promote microglial activation
(represented as increased cluster of differentiation [CD] 68
expression) [27]. Thus, regulation of microglial activation
by SCFAs depends upon the particular type and concen-
tration of SCFA being applied. These opposing regulatory
roles of butyric acid and propionic acid in glial cell acti-
vation also apply to astrocytes. Propionic acid has been
reported to increase expression of the astrocytic marker
glial fibrillary acidic protein (GFAP), while butyric acid
was found to reduce its expression [31–33]. Thus, an
increase in SCFA-producing bacteria in the gut may have
an effect upon the neuroinflammatory response controlled
by microglia and synaptic regulation mediated by
astrocytes.
2.4 Enteroendocrine Signalling
Enteroendocrine cells (EECs) are specialized cells of the
intestine, which are capable of producing peptides/sig-
nalling molecules (i.e. 5-HT, cholecystokinin [CCK], glu-
cagon-like peptide [GLP]-1 and peptide YY [PYY]),
chemosensing gut luminal contents and mediating energy
homeostasis [34]. EECs are distributed along the entire
length of the gastrointestinal mucosa and are suggested to
represent approximately 1% of epithelial cells in the gut
lumen [34, 35]. GLP-1, PYY and CCK are all released
from EECs following food intake, particularly after
ingestion of fats and carbohydrates. These peptides/hor-
mones act by binding to their cognate receptors upon the
vagus nerve to inhibit gastric emptying, induce satiety and
reduce meal size [34]. Moreover, GLP-1 and PYY have
both been shown to play a role in energy expenditure (for a
review, see Bauer and colleagues [36]). Receptors for these
peptides are expressed centrally in regions such as the
nucleus of the solitary tract and the hypothalamus. Con-
sequently, these gut peptides may mediate satiety and their
other behavioural responses by directly binding to their
cognate receptors in the brain. However, whether some of
these gut peptides are capable of reaching the brain directly
is unknown. GLP-1, for instance, is rapidly metabolized by
dipeptidyl peptidase IV at its site of secretion, and it is
unlikely to reach the CNS to activate its receptors [34].
Interestingly, there is evidence to indicate that bacterial
commensals are capable of regulating enteroendocrine
signalling, which is not surprising, given that these cells are
directly exposed to bacterial commensals in the gut. Germ-
free mice display alterations in the numbers of EECs in the
ileum and colon. Moreover, these animals exhibit attenu-
ated expression of PYY, GLP-1 and CCK, which suggests
that the microbiota may stimulate production of these
satiety peptides [37]. Recently, it has been determined that
proteins secreted from Escherichia coli are capable of
stimulating release of GLP-1 and PYY from EECs [38].
One protein produced by gut Escherichia coli that may
facilitate the release of GLP-1 and PYY is caseinolytic
protease B (ClpB). Breton and colleagues [38] have sug-
gested that ClpB, being an antigen mimetic of a-me-
lanocyte-stimulating hormone (a-MSH), may increase the
release of the satiety peptides by binding to melanocortin
receptor 4 (MCR4) upon EECs. This is a plausible mech-
anism, as stimulation of MCR4 upon EECs has previously
been shown to increase secretion of GLP-1 and PYY
peptides [39].
SCFAs have been shown to influence secretion of satiety
peptides from EECs. The microbial metabolites increase
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secretion of CCK, PYY and GLP-1 through binding to their
cognate FFAR1 and FFAR3 receptors, which are also
expressed upon EECs [40, 41]. Nøhr and colleagues [41]
demonstrated that propionic acid and other agonists of
FFAR1 and FFAR3 are capable of increasing the release of
GLP-1 from colonic crypt cultures. Further support for this
regulatory role of the gut microbiota has been seen with
prebiotics. Oligofructose and other inulin-type fructan
prebiotics promote satiety in rats, which appears to be
dependent upon increasing the level of GLP-1 while also
decreasing ghrelin levels in the intestine [42, 43]. This
effect of oligofructose has also been observed in humans
[44]. Prebiotic supplementation may promote satiety by
increasing the production of certain SCFAs, which in turn
modulate EECs and their secretion of hormones and pep-
tides, such as GLP-1 and ghrelin.
2.5 Tryptophan Metabolism
Tryptophan is a key dietary amino acid whose metabolites,
kynurenine and 5-HT, are incorporated into energy meta-
bolism and neurotransmission, respectively. 5-HT is a
fundamental neurotransmitter, which regulates physiolog-
ical processes such as mood, appetite, aggression and sleep
[45]. Moreover, the mechanism of action of conventional
antidepressants involves enhancing levels of central 5-HT
to produce a therapeutic effect, which highlights the
importance of agents that augment central 5-HT [46].
Aside from the 5-HT pathway, the majority of tryptophan
is metabolized into kynurenine in the liver via the enzy-
matic actions of tryptophan-2,3-dioxygenase (TDO) for
energy production, or following an inflammatory stimulus
by indoleamine-2,3-dioxygenase (IDO) [47, 48]. Evidence
suggests that the gut microbiota can regulate the metabo-
lism of tryptophan, which affects the levels of kynurenine
and 5-HT that can be produced. For instance, germ-free
mice have been found to have higher levels of circulating
tryptophan, along with lower levels of 5-HT, than con-
ventionally colonized mice [49, 50]. This may be due to a
reduction in colonic expression of tryptophan hydroxylase
(the rate-limiting enzyme in 5-HT synthesis) [51]. Fur-
thermore, these germ-free mice have a lower circulating
kynurenine-to-tryptophan ratio than conventionally colo-
nized mice, indicating a reduction in the amount of
kynurenine being produced. This is somewhat surprising,
given that germ-free mice have higher circulating trypto-
phan levels. However, it could be that the absence of
microbiota affects expression of the kynurenine-producing
enzymes (IDO and TDO). Interestingly, the increase in
circulating tryptophan in germ-free mice translated into
increases in the level of 5-HT and 5-HT turnover in the
hippocampus. This increased circulating tryptophan and
elevated hippocampal 5-HT turnover was evident in male
mice but not in female mice, which may have been due to
an effect of the oestrous cycle on the serotonergic system
[50].
Probiotic treatment has also been shown to influence
tryptophan, kynurenine and 5-HT levels. Long-term treat-
ment of rats with Bifidobacterium infantis 35624 increased
circulating tryptophan levels while reducing the kynur-
enine-to-tryptophan ratio, possibly through enhancement of
conversion of kynurenine into kynurenic acid [52]. More-
over, rats treated with Bifidobacterium infantis had lower
levels of 5-hydroxyindole acetic acid (5-HIAA) in the
frontal cortex, suggesting that the probiotic altered central
serotonergic transmission to some degree. In terms of
regulating kynurenine synthesis, Lactobacillus in the gut
may attenuate the conversion of tryptophan to kynurenine
by inhibiting IDO. Lactobacillus johnsonii supplementa-
tion lowered circulating kynurenine levels in rats with
concomitant increases in 5-HT being observed in the ileum
and in circulation. This effect of Lactobacillus johnsonii is
believed to be mediated by the ability of lactic acid bacteria
to produce H2O2, as peroxide is capable of activating the
peroxidase function of IDO, which subsequently inhibits its
kynurenine-producing capabilities [53]. Increased circu-
lating and central kynurenine metabolites have been iden-
tified in autism, schizophrenia, depression and
neurodegenerative diseases, such as Alzheimer’s and motor
neuron disease [48, 54]. Thus, the ability of the microbiota
to regulate the kynurenine pathway represents the potential
to target the microbiota in conditions with elevated
kynurenine levels.
3 Targeting the Gut Microbiota
‘‘The Force is a pathway to many abilities that some
consider to be… unnatural.’’ (The Emperor, Star
Wars: Episode III—Revenge of the Sith)
There is substantial evidence indicating that the gut
microbiota play a role in various metabolic, gastrointesti-
nal, neurological and psychiatric disorders. Consequently,
understanding how the microbiota can be targeted may lead
to development of microbiota-based therapies for these
various conditions.
3.1 Prebiotics
Prebiotics refer to non-digestible fibres that are selectively
metabolized by the intestinal tract and promote the pro-
liferation of beneficial Lactobacillus and Bifidobacterium
[55]. The main prebiotics include fructans (fructo-
oligosaccharides [FOS], inulins, oligofructose) and glucans
(galacto-oligosaccharides [GOS]). These prebiotics serve
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to enhance the levels of beneficial Bifidobacterium (bifi-
dogenic properties) in the gut. For instance, B-GOS—a
novel prebiotic produced from galactosidases derived from
Bifidobacterium bifidum—was found to have a substantial
bifidogenic effect in young healthy volunteers [56]. Fruc-
tans derived from agave plants also increased the levels of
Bifidobacterium and Lactobacillus in faecal samples from
healthy human participants [57]. These prebiotics are also
effective in the elderly. B-GOS and FOS increased the
levels of Bifidobacterium and Bacteroides in the faeces of
elderly individuals [58, 59]. Given the reported decreases
in levels of Bifidobacterium in the gut with age [60], pre-
biotic supplementation may help to maintain healthy gut
microbiota in elderly individuals and mitigate the risks of
age-related gastrointestinal and psychiatric diseases.
Additionally, both GOS and FOS increase production of
SCFAs, presumably as a consequence of modulating the
population of the gut bacterial commensals [58, 61]. Pre-
biotics (oligofructose) have also been shown to improve
gastrointestinal homeostasis by reducing intestinal perme-
ability and improving tight junction integrity, which may
be beneficial for treating gastrointestinal disorders where
barrier function is compromised [62].
3.2 Probiotics
Probiotics are defined as living microorganisms that confer
health benefits to the host when administered [63]. In order
for a microbe to be classified as a probiotic, it must meet
certain criteria. First, the production process for the pro-
biotic for administration to animals/humans must remain
constant, in that there must be no variation in colony-
forming units of the probiotic from one batch to the next.
Second, the bacteria must survive the physiological stresses
that are associated with its transport to the colon. These
include the host’s pH, stomach acid production and expo-
sure to biliary salts. Finally, the probiotic must confer a
beneficial effect on the host without causing any adverse
side effects [63]. The main bacterial genera used as pro-
biotics in both animal and human studies are the Lacto-
bacillus and Bifidobacterium genera [16, 63–65]. These
probiotics enhance the composition and diversity of the gut
microbiota. For instance, a probiotic mixture composed of
Lactobacillus rhamnosus and Lactobacillus helveticus
increased the level of Bacteroides and Firmicutes in
immunodeficient mice [66]. These probiotics have multiple
beneficial effects upon host physiology. For instance,
Lactobacillus acidophilus enhances intestinal barrier
tightness by up-regulating expression of the tight junction
protein, occludin [67]. The ability of probiotics to reduce
intestinal permeability represents the potential to block the
bacterial translocation that occurs in conditions such as
IBS, depression and autism. Other beneficial effects of
probiotics include enhanced wound healing. Lactobacillus
reuteri enhances wound healing by increasing secretion of
oxytocin, which in turn activates T regulatory cells to
promote healing [13]. Probiotic supplementation has also
been shown to reverse age-related deficits in long-term
potentiation, which suggests that they may be a useful
intervention in attenuating memory deficits in the elderly
[68]. When considering the beneficial behavioural effects
of probiotics, it must be noted whether the bacterial strain
being administered is responsible for these effects directly
or by an indirect mechanism through alteration of the
composition of the microbiota. Bacteria have evolved
mechanisms of communication (i.e. quorum sensing), such
that one bacterial species may suppress the growth of
another in the gut [69]. A probiotic may suppress or
enhance the growth of other bacterial species in the gut,
leading to global changes in the composition of the
microbiota. Thus, the behavioural effects of probiotics may
arise through alteration of the composition of the micro-
biota. A concern regarding use of probiotics as a potential
treatment is their mechanism of action. Probiotics do not
have as definitive a mechanism of action as an antide-
pressant, for example, and are likely to exert their known
beneficial effects through numerous pathways, some of
which might still be unknown. Furthermore, the mecha-
nism of action or efficacy of probiotics may vary from one
individual to another because of variations in the compo-
sition of the gut microbiota from person to person.
Nonetheless, there are considerable data to suggest that
probiotics exert a beneficial effect upon host health and
could potentially be used to treat neuropsychiatric disor-
ders [63, 65, 70].
3.3 Antibiotics
Antibiotics are our first line of pharmacological defence
against bacterial infections. Although they target patho-
genic bacteria, consuming antibiotics is also detrimental to
the indigenous flora in our gut. Antibiotic treatment (van-
comycin and imipenem) has been shown to decrease the
microbial load and to reduce microbial diversity in rats.
This reduction was attributed to losses in the operational
taxonomic units of the two major gut phyla: Bacteroidetes
and Firmicutes [71]. The reduction in microbial diversity
was maintained for 3 months following cessation of an
acute antibiotic treatment regime, indicating that even a
brief exposure to antibiotics is sufficient to induce long-
lasting alterations in the gut microbiota [71]. This effect of
antibiotics upon gut flora is also observed in humans, albeit
with some minor differences in the response of the
microbiota to these drugs. The broad-spectrum fluoro-
quinolone and b-lactam antibiotics increased the microbial
load with a concomitant reduction in microbial diversity,
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while also increasing the Bacteroidetes-to-Firmicutes ratio
in faecal samples from patients receiving a 7-day course of
the medication [72]. At the species level, this study showed
that antibiotics increased the proportion of several
unknown taxa belonging to the Gram-negative Bacteroides
genus, while also reducing taxa belonging to the Firmicutes
phyla [72]. Recently, Korpela and colleagues [73] showed
that a course of macrolide antibiotics was capable of
inducing long-lasting alterations in the composition of the
microbiota in children, which was associated with devel-
opment of obesity and asthma. Interestingly, penicillin did
not have as profound an effect upon the composition of the
microbiota as macrolides did in that study, which suggests
that the effect of antibiotics upon the bacterial composition
of the gut may depend upon the class of drug being pre-
scribed. However, Cox and colleagues [74] demonstrated
in mice that penicillin is also capable of inducing long-
lasting metabolic changes when administered at birth.
Consequently, these studies indicate that even short-term
use of antibiotics in early life or in adulthood is capable of
inducing long-lasting changes in the gut microbiota, which
(particularly with early life use) may predispose patients to
metabolic and immunological abnormalities.
Given that antibiotics alter the composition of the gut
microbiota, these drugs will most like have some effect
upon the microbiota–gut–brain axis. In a recent study by
Tochitani and colleagues [75], male mice whose mothers
had consumed a cocktail of antibiotics during pregnancy
displayed deficits in locomotor activity and weighed less.
However, use of normal mice to foster pups born from
antibiotic-treated mothers corrected this loss of weight.
Thus, it is likely that the effect of maternal antibiotic
administration upon offspring weight and locomotor
activity is a consequence of the poor nutritional state of the
mothers following alteration of their microbiota with
antibiotics, rather than a direct effect of antibiotics upon
neurodevelopment. Work from our laboratory has shown
that neonatal vancomycin administration to rats induced
dysregulation in the gut microbiota, which persisted into
adulthood, along with increasing visceral sensitivity. This
antibiotic-induced increase in visceral sensitivity was
independent of any effect upon depressive or anxiety-re-
lated behaviour [76]. However, some studies have shown
that antibiotic-mediated alterations in the gut microbiota
are associated with anxiolysis and cognitive deficits, along
with reductions in hippocampal brain-derived neurotrophic
factor (BDNF) [77]. This is in accordance with work from
Bercik and colleagues [17], who demonstrated that an
antimicrobial cocktail produced anxiolytic effects in mice.
However, this was associated with an increase in hip-
pocampal BDNF. This may have been due to the differ-
ences in the antibiotic cocktails used in both studies and in
the different strains of mice used. Nonetheless, antibiotic-
mediated dysregulation of the microbiota–gut–brain axis
can be reversed following treatment with probiotics, as
Lactobacillus paracasei has been shown to attenuate
antibiotic-mediated increases in visceral sensitivity [78].
This is presumably due to restoration of the gut microbial
community following probiotic intake.
4 Impact of the Gut Microbiota on Central
Nervous System Homeostasis
‘‘Don’t underestimate the Force.’’ (Darth Vader, Star
Wars: Episode IV—A New Hope)
Germ-free studies in mice have provided considerable
insight into how the gut microbiota affect CNS home-
ostasis [79]. Several studies have documented that the
bacterial commensals regulate neurotransmission, neuro-
genesis, the inflammatory status of the brain and activation
of the hypothalamic–pituitary–adrenal (HPA) axis. This
role of the microbiota is quite interesting when we consider
that all of the aforementioned neurophysiological processes
are affected in neuropsychiatric conditions.
4.1 Neurotransmission
4.1.1 c-Aminobutyric Acid
GABA is the main inhibitory neurotransmitter in the CNS,
and dysfunctions in this transmitter system are linked to
mood disorders, such as depression, anxiety and autism
[80]. Interestingly, the bacterial commensals in our gut—
specifically, lactic acid–producing bacteria—produce this
inhibitory amino acid. For instance, Lactobacillus brevis
and Bifidobacterium dentium derived from the human
intestine have been shown to be efficient producers of
GABA derived from monosodium glutamate [81]. These
bacteria produce GABA in a manner similar to the way in
which it is synthesized in the CNS, through irreversible
alpha-decarboxylation of L-glutamate to GABA via the
enzymatic actions of glutamic acid decarboxylase (GAD)
[82, 83]. How GABA derived from the gut microbiota
affects GABAergic neurotransmission has not been fully
elucidated. It remains a matter of debate whether this
peripherally derived GABA is capable of crossing the BBB
either through diffusion or through active transport [84].
However, Takanaga and colleagues [85] provided evidence
for expression of a GABA transporter at the BBB. Subse-
quently, GABA may be able to enter the CNS via this
transporter, and this may represent a means as to how the
bacterial commensals regulate central GABAergic trans-
mission. In support of this, spectroscopic analysis of
cerebral metabolites revealed that Lactobacillus rhamnosus
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(JB-1) increased the central level of GABA in mice [86].
Additionally, it appears that the gut microbiota can indi-
rectly regulate GABAergic neurotransmission via the
vagus nerve. The anxiolytic and antidepressant-like effects
of Lactobacillus rhamnosus (JB-1) supplementation were
associated with an increase in expression of the a2 subunit
of the GABAA receptor, along with a concomitant reduc-
tion in expression of the a1 subunit of the GABAA receptor
in the hippocampus, which was dependent upon the
integrity of the vagus nerve [11]. Thus, it would appear that
the beneficial behavioural effects of Lactobacillus involve
modulation of the GABAergic transmitter system.
4.1.2 Catecholamines: Dopamine and Noradrenaline
Noradrenaline and dopamine are two crucial neurotrans-
mitters in the mammalian brain. These two chemicals
control complex physiological processes, such as motiva-
tion and reward, awareness, motor control and regulation
of the endocrine axes. Dysfunction of these two transmitter
systems has been linked to various neurological and psy-
chiatric disorders, such as Parkinson’s disease and
depression. While these two catecholamines act as neuro-
transmitters in the CNS, they are also produced by the gut
microbiota. Germ-free mice display substantially lower
levels of noradrenaline and dopamine in the lumen of the
caecum than specific-pathogen-free mice, which suggests
that the gut microbiota are a potential source of cate-
cholamines [87]. In support of this, some species of bac-
teria express transcripts with a similar sequence to tyrosine
hydroxylase, the rate-limiting enzyme in noradrenaline and
dopamine synthesis [88]. In terms of what strain of bacteria
of the microbiota produce catecholamines, lactic acid–
producing bacteria are known to synthesize dopamine in
culture [89]. However, it is unlikely that these microbe-
produced catecholamines have any effect upon their cor-
responding central metabolites, as peripherally synthesized
dopamine is unable to cross the BBB. Nonetheless, the
microbiota also appear to be able to modulate central cat-
echolaminergic neurotransmission. Analysis of cerebral
metabolites from germ-free mice revealed lower levels of
the amino acid tyrosine—the rate-limiting substrate for
noradrenaline and dopamine synthesis—in comparison
with ex-germ-free controls. This corresponded with a
greater level of dopamine in the brains of germ-free mice,
suggesting that the absence of microbiota increased the
levels of catecholamines in the brain [90]. Nishino and
colleagues [91] also noted increased levels of nora-
drenaline and dopamine in the brains of germ-free mice
relative to ex-germ-free controls. However, replenishment
of the animals with microbiota increased dopamine and
noradrenaline turnover in the prefrontal cortex and hip-
pocampus of ex-germ-free mice, demonstrating that the
microbiota exert a regulatory effect upon catecholaminer-
gic transmission in the brain.
4.1.3 Histamine
Histamine is produced from the dietary amino acid his-
tidine through the enzymatic actions of histidine decar-
boxylase. While histamine has potent immunoregulatory
properties, it also acts as a neurotransmitter and is linked
to central processes such as circadian rhythms, food
intake, learning and pain perception [92]. Evidence
suggests that the microbiota are capable of synthesizing
this molecule in the gut, which may have an impact
upon its availability in the brain. For instance, the pro-
biotic Lactobacillus reuteri expresses the genes for his-
tidine decarboxylase, indicating that it is a proficient
synthesizer of histamine. Supplementation of Lacto-
bacillus reuteri cultures with histidine has been shown to
increase histidine decarboxylase expression, as well as
production of histamine [93]. Interestingly, Lactobacillus
reuteri inhibited production of the pro-inflammatory
cytokine tumour necrosis factor (TNF)-a in myeloid
progenitor cells through production of histamine [93].
This inhibitory effect of Lactobacillus reuteri upon
TNF-a production appears to be dependent upon acti-
vation of the H2 histamine receptor and, subsequently,
activation of the MEK/ERK mitogen-activated protein
kinase (MAPK) signalling pathway. This immunomod-
ulatory role of histamine may help to explain why his-
tamine is required for controlling infection in the enteric
nervous system [94]. Furthermore, blockade of H2
receptors has been shown to reduce mucus production
and lead to an increase in gut barrier dysfunction [95].
Thus, alterations in histaminergic signalling in the gut
may contribute to translocation of bacteria from the
lumen into the systemic circulation, which is thought to
occur in conditions such as IBS, depression and autism.
Diet may also influence histamine production through
modulation of the gut microbiota. IBS patients fed a diet
composed of low-fermentable oligosaccharides, disac-
charides, monosaccharides and polyols (FODMAP)
reported an improvement in their IBS symptom severity
score, which corresponded with an increase in Acti-
nobacteria richness, as well as a decrease in urinary
histamine levels [96]. This association between diet and
histamine levels is potentially quite important for the
treatment of IBS, given that elevated levels of histamine
have been documented in patients with this gastroin-
testinal condition [97]. While the microbiota have been
shown to influence local histamine production in the gut
and in the circulation, more work is required to deter-
mine whether they can influence central histaminergic
transmission.
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4.2 Microbiota Regulation of Neurotrophic Factors
Interestingly, research now strongly suggests that expres-
sion of BDNF is under the influence of the gut microbiota.
Long-term antibiotic administration in adolescent mice
results in depletion of the gut microbiota, along with a
concomitant reduction in hippocampal BDNF messenger
RNA (mRNA) expression [77]. Similarly, male mice raised
in a germ-free environment and devoid of gut microbiota
also display reduced BDNF expression, as well as altered
neuronal morphology in the hippocampus, relative to
conventionally colonized control mice [50, 98]. However,
Neufeld and colleagues [99] noted increased BDNF levels
in the hippocampus of female germ-free mice. Given that
there are differences in serotonergic transmission, as well
as in BDNF expression, between male and female germ-
free mice, it suggests that the microbiota–gut–brain axis is
regulated in a sexually dimorphic manner.
Supplementation with either prebiotics or probiotics
enhances the levels of the neurotrophin in the brain. Long-
term administration of the prebiotics FOS and GOS to rats
increased expression of BDNF mRNA within the dentate
gyrus [100]. Both GOS and FOS increased Bifidobacterium
levels in faecal pellets, and this bacterial species has pre-
viously been associated with an increase in hippocampal
BDNF [101], so this may be one potential mechanism
through which prebiotics increase expression of the neu-
rotrophin. Studies assessing the effect of probiotic sup-
plementation on hippocampal BDNF suggest that
probiotics also promote expression of the neurotrophin
under conditions of chronic stress, inflammation and aging.
Bifidobacterium longum NCC3001 prevented reductions in
hippocampal BDNF following chronic immune activation
with the parasite Trichuris muris [101]. Furthermore,
Lactobacillus helveticus NS8 reversed chronic stress-in-
duced reductions in BDNF [102]. While it is unknown how
the gut microbiota directly influence central BDNF
expression, this modulatory role of the microbiota lends
credence to use of probiotics for the treatment of mood
disorders such as depression, which is associated with
dysfunctional immune activation, chronic psychological
stress and a reduction in expression of the neurotrophic
factor. The probiotic VSL#3 increased hippocampal BDNF
in both young and aged mice while also improving long-
term potentiation in aged animals [68]. These are promis-
ing data, as they suggest that probiotics may be useful in
attenuating age-related memory deficits. Thus, probiotic
supplementation in the elderly may help to protect against
age-related cognitive decline and Alzheimer’s disease.
In addition to regulation of expression of BDNF, the
evidence also suggests that the gut microbiota are capable
of influencing expression of other neurotrophic factors such
as glial-derived neurotrophic factor (GDNF) and nerve
growth factor (NGF). For instance, expression of NGF in
the colon was attenuated following treatment of mice with
antibiotics, which was associated with a reduction in vis-
ceral pain responses [103]. One way in which the bacterial
commensals in the gut may promote intestinal expression
of neurotrophins is through microbial signalling via TLRs,
as Brun and colleagues [104] demonstrated that the TLR-2
agonist Pam3CSK4 induced expression of NGF, BDNF
and GDNF in ileal smooth muscles cells. This ability of the
gut microbiota to regulate neurotrophin expression within
the gut is likely to have an effect upon neurotransmission
within the enteric nervous system, and this warrants further
investigation.
4.3 Microbiota Regulation of Microglial Activation
The brain’s resident immune cells—the microglia—are
also found to be under the regulation of the microbiota
[105, 106]. Consequently, the bacterial commensals in our
gut have the potential to control the neuroinflammatory
response that is often found to be exaggerated in psychi-
atric and neurodegenerative conditions [107, 108]. Early
work with the tetracycline-derived antibiotic minocycline
demonstrated that this antimicrobial compound was cap-
able of inhibiting the activation and proliferation of
microglia. Although its actions are thought to be due to its
ability to stabilize microglia, a potential regulatory role of
the gut microbiota in the neuroimmune response must now
be also considered [109]. In light of this, when mice are
raised germ free, they are found to have an increased
number of IBA? microglia in the cortex and hippocampus.
These microglia display an immature phenotype, as they
lack markers of maturity—such as CD44, CD62L and
major histocompatibility complex (MHC) class II—while
also failing to display an activated phenotype following
LPS administration [30]. This effect upon microglial
morphology and activation has also been observed fol-
lowing antibiotic treatment, which confirms that the
absence or depletion of the microbiota has a profound
effect upon the neuroinflammatory response [30]. The
regulatory effect of the microbiota upon the neuroinflam-
matory status of the brain also appears to be dependent
upon diet. Transplantation of gut microbiota from high fat
diet–fed mice to host mice resulted in increased protein
expression of the microglial markers IBA-1, TLR-2 and
TLR-4, indicative of microglial activation and neuroin-
flammation [110]. Transplantation of high fat diet–modu-
lated microbiota also decreased the central expression of a
tight junction protein, zona occludens (ZO)-1, which may
have facilitated the entry of peripheral inflammagens (i.e.
LPS) into the brain and caused the observed microglial
activation and neuroinflammation [110]. This relationship
between the gut microbiota and the brain highlights the
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importance of an appropriate diet and the detrimental effect
that obesity can have on the brain. The regulatory role of
the microbiota in the neuroinflammatory response may be
partly mediated by SCFAs, as neurotoxic levels of propi-
onic acid have been shown to increase microglial activation
[27], although butyric acid attenuates microglial activation
following LPS administration [29]. An increase in SCFA-
producing bacteria in the gut as a consequence of diet,
medication or infection may lead to increased levels of the
microbial metabolites in the brain, which in turn could
affect microglial activation.
The commensals in our gut also regulate the neuroin-
flammatory process in certain neurodegenerative condi-
tions, such as multiple sclerosis. Recent work from our
group has shown that the microbiota influence myelination
in the prefrontal cortex, which may have implications for
conditions such as multiple sclerosis, where there is a loss
of myelin [111]. Polysaccharide A (PSA) secreted from
Bacteroides fragilis was protective against demyelination
in a murine experimental autoimmune encephalomyelitis
(EAE) model of multiple sclerosis by increasing the con-
version of T helper 2 (Th2) cells into IL-10 producing
FoxP3? T regulatory cells in cervical lymph nodes
[112, 113]. Moreover, a probiotic mixture of various Lac-
tobacillus species attenuated the behavioural and histo-
logical deficits of EAE by lowering circulating pro-
inflammatory cytokines, such as interferon (IFN)-! and IL-
17. While the mechanism behind the beneficial effect of
this Lactobacillus probiotic mixture in reducing EAE
severity is unknown, it appears to be dependent upon
synthesis of IL-10, as knockout of the gene for this anti-
inflammatory cytokine blocked the therapeutic effect of the
probiotic [114]. This suggests that the microbiota could be
targeted as a potential prophylactic or treatment for mul-
tiple sclerosis and other neurodegenerative conditions.
4.4 Microbiota Regulation of Endocrine
and Hormonal Control
The HPA axis is the neuroendocrine system that governs
the physiological stress response of mammals. Exposure to
psychological or physical stressors results in activation of
the paraventricular nucleus of the hypothalamus, which
then stimulates secretion of corticotrophin-releasing factor
(CRF) from the median eminence. CRF is transported to
the anterior lobe of the pituitary via the hypophyseal portal
vein, where it stimulates secretion of adrenocorticotrophic
hormone (ACTH) into the general circulation. ACTH acts
on the adrenal cortex to induce release of glucocorticoids,
such as cortisol (humans)/corticosterone (rats/mice). Glu-
cocorticoids regulate several important physiological pro-
cesses, such as metabolism, immunity, adiposity and even
neurogenesis [115]. Consequently, excessive production of
these stress hormones has adverse effects on health. Sev-
eral studies have documented that when mice and rats are
raised germ free, these animals have elevated levels of
circulating ACTH and corticosterone following exposure to
stress [50, 99, 116, 117]. Moreover, expression of the
glucocorticoid receptor was found to be lower in the hip-
pocampus of germ-free mice relative to specific-pathogen-
free mice. Given that the glucocorticoid receptor is a glu-
cocorticoid-inducible gene, this down-regulation in its
expression may be an adaptive response to excessive levels
of circulating corticosterone [117]. Furthermore, when
germ-free mice are reconstituted with microbiota, the
enhanced HPA axis response to stress is partly reversed.
However, this appears to be dependent upon the age of the
animal, as it was effective in young mice but not in adult
mice [118]. Thus, there is a critical period in development
during which the microbiota can modulate stress-induced
activation of the HPA axis.
Probiotics have been shown to modulate activation of
the HPA axis, which may relate to their beneficial effects
upon behaviour. Interestingly, this effect of probiotic sup-
plementation upon corticosterone levels appears to be
bacterial strain specific. For instance, Lactobacillus sali-
varius and Lactobacillus farciminis have both been shown
to decrease stress-induced corticosterone secretion
[119, 120]. However, Bifidobacterium has not been found
to curtail levels of the stress hormone despite its beneficial
behavioural effects [52, 65]. This would suggest that dif-
ferent probiotic strains possess distinct mechanisms of
action in producing their beneficial behavioural effects.
The data regarding the effects of prebiotics upon HPA axis
activation are quite limited at the moment. The prebiotics
30sialyllactose and 60sialylactose were found to have no
effect upon circulating corticosterone following social
disruption stress in mice, despite producing an anxiolytic
effect [121]. However, the prebiotic B-GOS has been
shown to reduce the cortisol awakening response in
humans, so there is some evidence to suggest that prebi-
otics are capable of modulating the levels of the stress
hormone [3]. Further work is required to determine the
mechanism underlying how the microbiota regulate acti-
vation of the HPA axis.
Although the data are limited at the moment, the evi-
dence suggests that other hormones are also under the
control of the microbiota. For instance, recent work from
our laboratory has shown that expression of vasopressin
and oxytocin in the hypothalamus of mice is reduced fol-
lowing treatment with antibiotics [77]. This suggests that
the microbiota either directly or indirectly regulate the
expression of these peptide hormones. Work from Erdman
and colleagues [13] would suggest the latter, as they
showed that Lactobacillus reuteri enhanced wound healing
through increased oxytocin release from the hypothalamus.
1028 E. Sherwin et al.
This effect of Lactobacillus reuteri was dependent upon
the integrity of the vagus nerve, as deafferentation of the
nerve blocked this effect of the probiotic. Recently, it was
shown that Lactobacillus reuteri ameliorated social deficits
in murine offspring of high fat diet–fed mothers, which was
associated with an increase in oxytocin immunoreactivity
within the paraventricular nucleus of the hypothalamus
[122]. Such promising data would suggest that there are
certain species of gut bacteria that can modulate central
oxytocin levels.
It is interesting to speculate whether the microbiota
influences maternal behaviour, which is associated with
secretion of oxytocin. Tochitani and colleagues [75]
demonstrated that when female mice were administered
antibiotics throughout pregnancy, their offspring displayed
a mildly anxious phenotype. Interestingly, when pups born
from antibiotic-treated mothers were then fostered by non-
antibiotic-treated females, this behavioural phenotype was
ameliorated, demonstrating that depletion of the gut
microbiota affects maternal behaviour. Whether this
involves oxytocin is unknown, and other mechanisms are
likely at play, such as the effect of the antibiotic upon the
level of prebiotics/bacteria that are transferred to the off-
spring via the maternal milk. Nonetheless, it is an inter-
esting observation that the microbiota regulate maternal
behaviour. Given that gut microbes have recently been
shown to play a role in mediating social behaviour [77],
and that deficits in the social hormone oxytocin have been
documented in autism [123], further work is required to
decipher microbiota–peptide interactions in neurodevel-
opmental disorders [124].
5 The Gut–Microbiota–Brain Axis in Psychiatric
and Neurodevelopmental Disorders
‘‘There is a great disturbance in the Force.’’ (The
Emperor, Star Wars: Episode V—The Empire Strikes
Back)
5.1 Depression
Major depression is a stress-related mood disorder, char-
acterized psychologically by low mood, feelings of
worthlessness and suicidal ideation, and physiologically by
alterations in the HPA axis and the immune system, as well
as psychosomatic symptoms. As mentioned above, the gut
microbiota are capable of regulating activation of the HPA
axis and the immune system, and so it is interesting to
speculate as to whether the microbiota contribute towards
depression by affecting these two physiological systems.
Currently, there is little clinical evidence to suggest that
alterations in the gut microbiota occur in depression.
Although Naseribafrouei and colleagues [125] failed to
identify any differences in terms of microbial diversity
between depressed patients and controls, the levels of
Bacteroidetes were found to be lower in depressed patients.
However, in a recent study by Jiang and colleagues [126],
pyrosequencing of faecal samples from depressed patients
and healthy controls revealed increased diversity (using the
Shannon index) in the composition of the microbiota in
depressed patients. Of note, there was an increase in the
Bacteroidetes and Proteobacteria (which include the LPS-
expressing Enterobacteriaceae) phyla, with a concomitant
reduction observed in the numbers of Firmicutes. The
conflicting reports of microbial diversity in faecal samples
between these two studies may stem from the fact that
Naseribafrouei and colleagues used outpatients from a
neurological unit as controls, while Jiang and colleagues
used healthy subjects. Additional evidence of dysregulated
microbiota in depression comes from Maes and colleagues
[127], who demonstrated that a cohort of chronically
depressed patients displayed increased circulating levels of
immunoglobulin (Ig) A and IgM antibodies raised against
LPS expressed upon Gram-negative Enterobacteriaceae.
This would suggest that there is bacterial translocation
from the gut to the systemic circulation during chronic
depression, which would presumably lead to an inflam-
matory response that may be contributing towards the
mood disorder.
Animal models of depression have allowed us to better
understand how the gut microbiota may influence depres-
sion-like behaviours. Maternal separation is frequently
used as a model of early life stress that provokes a
depressive and anxiety-like phenotype, along with alter-
ations in monoamine turnover, immune function and HPA
axis activation [128–131]. Furthermore, there is consider-
able evidence that this model of early life stress also affects
the composition of the gut microbiota. Early work from
Bailey and Coe [132] demonstrated that maternal separa-
tion decreased faecal Lactobacillus in rhesus monkeys 3
days post-separation. Previous work from our laboratory
has also demonstrated the adverse effects of maternal
separation upon the microbiota–gut–brain axis in rats in
terms of increased colonic visceral sensitivity and disrup-
tion to the microbiota themselves. While it was not deter-
mined which species of bacteria in the microbiota were
affected by maternal separation, this study demonstrated
that early life stress has a profound effect upon the gut
commensals [128, 130]. Recent findings by De Palma and
colleagues [131] have elaborated upon the role of the
bacterial commensals in the gut in the development of
behavioural despair in the maternal separation model. In
their study, maternal separation increased circulating cor-
ticosterone in germ-free mice independently of depressive
or anxiety behaviour. This suggests that the microbiota are
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not necessarily required for stress-induced alterations in
HPA axis activity but are required for development of
anxiety and depression-like behaviours.
Other models of chronic stress/depression have also
been shown to induce alterations in the microbiota.
Olfactory bulbectomy is a rodent model of depression that
displays altered neuroendocrine and neuroimmune
responses and a behavioural phenotype that is similar to
what is observed in clinical depression. The model also has
strong predictive validity, as it responds only to long-term
antidepressant treatment [133]. Interestingly, Park and
colleagues [134] demonstrated that bulbectomy affects gut
transit and the composition of the microbiota by redis-
tributing the relative abundances of bacterial phyla. Park
and colleagues [134] demonstrated a similar shift in gut
microbial composition following central CRF administra-
tion. Thus, the altered microbial composition of the gut in
bulbectomized animals may be a consequence of their
altered neuroendocrine response. Given the criticisms of
the olfactory bulbectomy model, it is difficult to extrapo-
late these changes in the composition of the gut microbiota
in bulbectomized animals to what is observed in clinical
depression or even to other animal models of depression
[135]. Thus, it is important to assess the role of the gut
microbiota in other animal models of depression that are
more clinically relevant. Social defeat stress, for example,
exerted profound alterations in the operational taxonomic
units of the gut microbiota, which led to deficits in socia-
bility. A reduction in diversity was associated with
decreases in the abundance of Clostridium species, as well
as decreases in fatty acid production and biosynthesis
pathways leading to dopamine and 5-HT production [136].
This decrease in Clostridium abundance following social
defeat stress is in contrast to previous work from Bailey
and colleagues [137], who demonstrated an increase in the
relative abundance of Clostridium species following social
disruption stress. A stress-induced increase in the abun-
dance of Clostridium species may lead to translocation of
this Gram-positive bacterium to the circulation, which
could induce an inflammatory response and affect beha-
viour. Although there were considerable differences in
terms of the animal models of depression that were used
and the changes observed in the microbiota within these
models, all of these animal studies collectively highlight an
association between altered gut microbiota and depression-
like behaviour.
While no studies so far have assessed whether probiotics
or prebiotics are successful in the treatment of clinical
depression, several groups have documented the beneficial
effects of probiotics and prebiotics in healthy individuals
(see Table 1). Indeed, the idea that Lactobacillus strains
may improve quality of life and mental health is not a new
one. Dr. George Porter Phillips [138] first reported in 1910
that a gelatin-whey formula with live lactic acid bacteria
improved depressive symptoms in adults with melancholia.
More recently, 3-week supplementation with the prebiotic
B-GOS decreased the cortisol awakening response and
increased attentional vigilance towards positive stimuli [3].
This finding is consistent with those of a functional mag-
netic resonance imaging (fMRI) study, which demonstrated
that long-term administration of a probiotic mixture of
various Bifidobacterium and Lactobacillus species resulted
in reduced neural activity within a widely distributed brain
network in response to a task probing attention towards
negative stimuli [64]. A recent study by Steenbergen and
colleagues [139] further demonstrated the beneficial effects
of a Lactobacillus and Bifidobacterium mixed probiotic on
mood in healthy individuals. Moreover, clinical data from
healthy participants would suggest that probiotics are also
effective in alleviating behavioural symptoms of anxiety
[140]. Given that these studies have shown that both pre-
biotics and probiotics improve mood in healthy individuals,
this lends support to their use in treating depression and
anxiety. However, clinical trials of probiotics and prebi-
otics in depressed patients are required to fully determine
their efficacy in treating depression and anxiety.
Animal models have been useful in delineating the
underlying antidepressant and anxiolytic mechanisms of
action of probiotics. Interestingly, treatment with the pro-
biotic Bifidobacterium infantis 35624 attenuated the
immobility time of maternal separation rats in a forced
swim test while also normalizing their aberrant peripheral
immune response. However, the probiotic had no effect
upon circulating corticosterone levels, which again sug-
gests that bifidogenic-based probiotics affect behaviour
independently of regulating stress-induced alterations in
the HPA axis [129]. This is similar to what Savignac and
colleagues [65] reported when they showed that both Bi-
fidobacterium longum and Bifidobacterium breve attenu-
ated depressive and anxiety-like behaviours in mice.
However, neither strain had any effect upon stress-induced
(by forced swim test exposure) corticosterone release.
Interestingly, a probiotic containing both Bifidobacterium
longum and Lactobacillus helveticus attenuated circulating
corticosterone and adrenaline levels in mice following
exposure to water avoidance stress [120]. Such results
suggest that probiotic-regulation of the HPA axis may be
Lactobacillus dependent despite the beneficial effects of
both bacterial strains upon behaviour. Nonetheless, these
studies lend support to use of probiotics and prebiotics in
the management of psychiatric conditions.
5.2 Schizophrenia
Schizophrenia is a complex neuropsychiatric disorder char-
acterized by a cluster of symptoms, which includes psychoses,
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cognitive dysfunction, delusions, paranoia and apathy. Given
that the concordance rate for schizophrenia is greater in
monozygotic twins than in dizygotic twins, it is widely
accepted that schizophrenia has a genetic component in its
pathology [146]. However, genome-wide association studies
have found only a weak effect association for genetic factors
contributing to this neuropsychiatric disorder [147]. Thus, it is
likely that environmental factors (i.e. urban upbringing, drug
use, early life trauma) interact with underlying genetic defi-
cits, culminating in schizophrenic behaviour. Chronic gas-
trointestinal symptoms, such as gastritis and colitis, often
accompany schizophrenia. However, whether this reflects
altered brain-to-gut signalling or dysregulation of the micro-
biota is unknown [148, 149]. Nonetheless, there is some evi-
dence to suggest a potential role of the gut microbiota in this
neuropsychiatric disorder.
The development of the gut microbiota occurs synony-
mously with that of the brain. In fact, normal microbiota
are required to facilitate proper neurodevelopment
[150, 151]. Thus, we must consider the importance of how
we initially receive microbiota and how that affects the
brain. Infants who are delivered normally acquire their
Table 1 Clinical and preclinical evidence for the antidepressant and anxiolytic properties associated with targeting the gut microbiota
Behavioural outcomes Physiological outcomes References
Clinical evidence
B-GOS Increased cognitive processing of
positive versus negative
attentional vigilance
Reduced cortisol awakening response [3]
Lactobacillus casei strain
Shirota
Reduced anxiety scores in patients
with chronic fatigue syndrome
Increased numbers of Lactobacillus and Bifidobacterium
in faecal samples
[141]
Improved mood in individuals with
a low mood prior to taking the
probiotic
NA [142]
Probiotic formulation:
Lactobacillus helveticus and
Bifidobacterium longum
Reduced psychological distress as
measured by the HADS
Reduced 24-h UFC levels [140]
Multispecies probiotic
formulation: Lactobacillus
and Bifidobacterium species
Reduced cognitive processing of
sad mood; decreased aggressive
feelings and rumination
NA [139]
Preclinical evidence
FOS and GOS NA Increased BDNF, NR1 and NR2A mRNA, and protein
expression in the dentate gyrus and frontal cortex
[100]
30Sialyllactose and
6’sialyllactose
Anxiolytic effect in mice exposed to
SDR
Prevented SDR-mediated reduction in the number of
immature neurons
[121]
Bifidobacterium infantis Reduced immobility time of
maternally separated rats in a
forced swimming test
Attenuated exaggerated IL-6 response in maternally
separated rats following concanavalin A stimulation
[129]
Bifidobacterium breve Improved depressive and anxiety-
related behaviours in mice
No effect upon circulating corticosterone [65]
Bifidobacterium longum Anxiolytic effect in step-down
inhibitory avoidance
Anxiolytic effect mediated via the vagus nerve [16]
Lactobacillus plantarum
PS128
Reduced immobility time and
increased sucrose preference in
ELS mice
Decreased basal and stress-induced circulating
corticosterone levels; attenuated circulating TNF-a and
IL-6 levels while increasing IL-10 levels in ELS mice
[143]
Lactobacillus rhamnosus Reduced immobility time in
the forced swim test
Decreased stress-induced circulating corticosterone
secretion and altered central GABA receptor subunit
expression
[11]
Lactobacillus fermentum NS9 Reduced ampicillin-induced anxiety
behaviour
Decreased ampicillin-induced corticosterone secretion
and increased hippocampal mineralocorticoid receptor
and NMDA receptor levels
[144]
Butyric acid Reduced immobility time in
Flinders sensitive line rats
exposed to a forced swim test
Increased BDNF expression within the prefrontal cortex [145]
BDNF brain-derived neurotrophic factor, ELS early life stress–exposed, FOS fructo-oligosaccharide, GABA c-aminobutyric acid, GOS galacto-
oligosaccharide, HADS Hospital Anxiety and Depression Scale, IL interleukin, mRNA messenger RNA, NA not assessed, NMDA N-methyl-D-
aspartate, SDR social disruption stress, TNF tumour necrosis factor, UFC urinary free cortisol, NR NMDA Receptor
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microbiota by passing through the birth canal. Their
microbiota are akin to vaginal and faecal bacteria, whereas
when infants are born by caesarean section, their micro-
biota resemble those of the maternal skin and hospital
environment, with fewer Bifidobacterium species and more
Clostridium species [152, 153]. A recent clinical study
found a weak association between birth by caesarean sec-
tion and the risk of developing psychosis [154]. However,
this association did not persist in sibling-matched analysis,
which suggests that confounding genetic and environ-
mental factors may account for this association between
caesarean birth and psychosis. Nonetheless, there have
been reports of increased urinary excretion of phenylala-
nine metabolites derived from Clostridium species in
schizophrenic patients, which would suggest that perhaps
there is an overabundance of this unfavourable bacterial
strain in the microbiota in schizophrenic patients [155].
Whether Clostridium contributes towards the behavioural
abnormalities observed in schizophrenia is unknown.
However, how we receive our microbiota may be an
influential factor in precipitating this neuropsychiatric
disorder.
An additional environmental risk factor for
schizophrenia is infection with the protozoan Toxoplasma
gondii. Infection with the protozoan has been strongly
correlated with schizophrenia, and medications used to
treat psychosis are capable of inhibiting its replication
in vitro [156, 157]. Interestingly, toxoplasmosis in mice
induces gastrointestinal inflammation, along with
decreasing bacterial diversity in the ileum and increasing
bacterial translocation into the circulation [158, 159].
Dysregulation in the composition of the gut microbiota
following Toxoplasma gondii infection may contribute
towards the ability of the protozoan to induce psychoses,
perhaps through stimulation of the immune system or
through production of bacterial metabolites that have a
pro-psychotic effect. Viruses—specifically, those viruses
that infect bacteria (bacteriophages)—are also associated
with schizophrenia. Bacteriophages infect bacteria and
subsequently alter their metabolism and replication, which
could affect the composition of the microbiota and their
ability to signal to the brain. The levels of the bacterio-
phage Lactobacillus phage phiadh were found to be ele-
vated in the oropharyngeal microbiota in schizophrenic
patients with comorbid immunological conditions [160].
The main Lactobacillus host for this bacteriophage is
Lactobacillus gasseri, a strain of bacteria that is found in
the oral and gastrointestinal mucosae and is linked with
host immune modulation [161]. Given that schizophrenia
is often comorbid with immunological conditions [162],
Lactobacillus phage phiadh may affect the microbiota in
schizophrenic patients, giving rise to aberrant immune
responses.
Medications used to treat schizophrenia (such as the
atypical antipsychotic olanzapine) are associated with
causing a range of metabolic side effects, such as weight
gain, increased fat accumulation and impairment of glu-
cose metabolism [163]. It has been well documented that
the gut microbiota have a role to play in energy regulation
and metabolism, and that alterations in the bacterial com-
mensals are associated with weight gain [164–166]. Inter-
estingly, olanzapine treatment has been shown to lead to a
reduction in the phylogenetic diversity of the gut micro-
biota in rats, with a reduction in the level of Bacteroidetes
and an increase in the level of Firmicutes [167, 168]. This
was associated with hyperphagia, an increase in visceral fat
and increased peripheral inflammation, all of which were
more prominent in female rats than in males [167]. Whe-
ther dysregulation of the microbiota following olanzapine
treatment is a direct effect of the atypical antipsychotic or
is secondary to the observed metabolic side effects is
unknown, although it is likely to be the latter. However, a
direct effect of olanzapine upon the gut flora cannot be
ruled out. Nonetheless, it is interesting to note that olan-
zapine has a more pronounced effect upon metabolism and
gut microbial composition in female rats, given that female
patients are more susceptible to weight gain mediated by
antipsychotic medication [169]. Gender dimorphism in
metabolism and immune function may factor into this
effect of olanzapine. Depletion of the microbiota following
antibiotic treatment has been shown to correct the meta-
bolic dysfunction induced by olanzapine while also
reversing the effects of the antipsychotic upon gut bacterial
composition [168]. The ability of antibiotics to reverse the
metabolic side effects associated with antipsychotic use
encourages development of prebiotic, probiotic or symbi-
otic (prebiotic and probiotic) therapies to tackle this clin-
ical issue.
5.3 Autism Spectrum Disorders
Autism spectrum disorders (ASD) refer to a cluster of
neurodevelopmental disorders characterized by the pres-
ence of repetitive behaviour and deficits in social interac-
tions and communication. Comorbid gastrointestinal
disorders are reported in up to 90% of children with ASD
and include constipation, diarrhoea, abdominal pain,
vomiting and poor nutritional absorption [170]. The evi-
dence suggests that these gastrointestinal disorders in ASD
are associated with dysregulation of the gut microbiota and
that the extent of gastrointestinal dysfunction can predict
the severity of autistic behaviour. Levels of Bacteroidetes
and Firmicutes are found to be altered in faecal samples
from autistic children [123, 171, 172]. Indeed, autistic
children show greater faecal microbiota diversity than
healthy children [173]. Greater diversity of the microbiota
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may increase the likelihood of the presence of harmful
bacteria, which may contribute towards the severity of
autistic behaviour. For instance, Parracho [174] noted that
faecal samples from children with ASD displayed greater
levels of the Clostridium histolyticum group (Clostridium
clusters I and II) than control subjects. Moreover, in a
Slovakian cohort of children with ASD, the levels of
Lactobacillus and Clostridium class 1 were higher in faecal
samples from autistic children than in those from control
children. The levels of Clostridium and Desulfovibrio have
been found to be higher in children with more profound
autism than in children with milder autism, which suggest
that perhaps these two bacterial species somehow dictate
the severity of autistic symptoms [123].
Further indications of a role of Clostridium in autism
have come from a small clinical study in which 11 children
with regressive autism were treated with the antibiotic
vancomycin. Autistic behaviour dramatically improved
during the 8-week vancomycin trial, with increased eye
contact and speech, along with a considerable decrease in
gastrointestinal symptoms. However, all children relapsed
following cessation of the trial [175]. Given that van-
comycin targets Clostridium species, this small study
seemingly confirms the detrimental role of this bacterial
species in ASD. How might the altered microbiota found in
children with ASD give rise to autistic behaviours/symp-
toms? A role of SCFAs has been implicated, as increased
levels of the microbial metabolites have been observed in
faecal samples from autistic children. Of note, levels of
acetic acid, butyric acid and propionic acid were all higher
in autistic children than in controls [176]. SCFAs regulate
the acidity of the gut by lowering the intestinal pH.
Increasing the acidic environment of the gut may promote
proliferation of Clostridium species, which may subse-
quently facilitate autistic behaviour. Additionally, SCFAs
are able to cross the BBB and possess neuroactive prop-
erties [24, 27, 28]. Thus, excessive production of SCFAs by
the gut microbiota in autistic children may cross the BBB
and have a detrimental effect upon neurodevelopment.
Animal models of autism allow us to more closely
investigate how the microbiota–gut–brain axis may be
perturbed in autistic individuals. Autistic symptoms such as
repetitive behaviour, deficits in communication and
reduced sociability can be mimicked in animals through
experimental manipulations, such as in utero exposure to
teratogens (valproic acid [VPA]) or inflammagens (polyi-
nosinic:polycytidylic acid [poly I:C]). Uterine exposure to
VPA induces deficits in social interaction in mice. Inter-
estingly, this deficit in sociability is evident in male mice
but not in female mice, which is similar to what is observed
in the clinical setting [177, 178]. In utero VPA exposure
has also been shown to result in gastrointestinal inflam-
mation, along with alterations in the gut microbiota,
observed as an increase in Firmicutes and a decrease in
Bacteroidetes. Moreover, uterine VPA exposure increased
caecal SCFA levels—specifically, butyric acid—in male
mice but not in female mice [177, 178]. Uterine exposure
of animals to the inflammagen poly I:C also produces
autism-like symptoms in rodents and primates, and is
referred to as the maternal immune activation (MIA) model
of autism [179, 180]. This model is quite interesting
because of its construct validity, as severe viral or bacterial
infection during the first and second trimesters of preg-
nancy is considered to be a risk factor for autism in humans
[181]. MIA induces dysregulation of the gut microbiota,
along with promoting autism-like features in mice [182].
Hsiao and colleagues [182] did not identify any differences
in the overall microbial diversity between MIA and con-
trols in terms of species richness. However, they did pin-
point differences in the diversity of the Clostridium and
Bacteroides operational taxonomic units, which they con-
cluded was the major driving force behind dysregulation of
the microbiota in MIA animals. This increased diversity of
Clostridium species in MIA animals parallels what is
observed in children with autism [123, 174]. Additionally,
treatment with Bacteroides fragilis corrected the MIA-in-
duced dysregulation of the gastrointestinal system and
microbiota, along with reversing some of the autism-like
behaviours induced by uterine poly I:C exposure [182].
The ability of Bacteroides fragilis to improve autism-like
behaviour while also improving gastrointestinal and
microbiota dysregulation highlights the potential of tar-
geting the gut microbiota for treatments for autism.
Interestingly, elevated levels of some SCFAs have also
been shown to induce autism-like symptoms. Propionic
acid, when administered in high or neurotoxic doses, pro-
duces a neuroinflammatory response while also altering
brain lipid composition and facilitating an autism-like
phenotype in adult rats [49, 183–185]. The dysregulation of
the gut microbiota that is observed in autism may lead to
excessive production of propionic acid that crosses into the
brain and gives rise to the neurophysiological and beha-
vioural profile of autism. While propionic acid may con-
tribute towards autistic behaviour, butyric acid has recently
been shown to improve repetitive behaviour in the BTBR
mouse model of autism [28]. Thus, SCFAs appear to have a
Janus-faced role in mediating autism-like behaviour. More
work is required to determine the precise molecular
mechanisms underlying the opposing effects of propionic
acid and butyric acid in autism-like behaviour.
While there has been substantial research into the dys-
regulation of the microbiota–gut–brain axis in ASD and the
potential beneficial effects of psychobiotics, more insight is
required to determine whether this dysregulation is causal
of the neurodevelopmental disorder or a consequential
comorbidity. Factors such as diet, hygiene, medication and
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susceptibility to stress have all been shown to affect the
microbiota, and these factors may account for the observed
dysregulation of the gut flora in ASD. For instance, anxiety
is found to be comorbid in between 11 and 84 % of chil-
dren and adolescents with ASD [186]. Increased anxiety in
ASD, and the ensuing stress that accompanies it, may
contribute towards the dysregulation of the gut microbiota
that is observed in autism. Thus, alterations in the bacterial
flora of the gut in autism may be a consequence of
comorbidity rather than the underlying cause of the
developmental disorder itself. The studies that demon-
strated altered microbiota in children with ASD had addi-
tional limitations. Most of these studies were
underpowered and did not control for factors that have an
impact upon the microbiota, such as diet, sex and prior
exposure to antibiotics [187]. Even short-term antibiotic
use has been shown to induce long-lasting changes in the
gut microbiota, which might account for the differences
reported between autistic children and normal children
[72]. Diet is also an important consideration, as many
autistic children display stereotyped diets that may affect
the diversity and composition of the gut microbiota. In a
recent study, 16S ribosomal RNA (rRNA) analysis
revealed an increase in the low-abundance Cyanobacteria/
chloroplast genus in children with ASD [188]. However,
the authors cautioned that this increase in chloroplast
sequences in ASD may have been due to ingestion of chia
seeds, which indicates that diet is an influential factor that
must be controlled for when investigating disturbances of
the microbiota in ASD. Furthermore, studies assessing an
effect of probiotics upon autistic behaviour in children
have been underpowered and lacking in experimental
design to reveal any potential beneficial effect
[123, 189, 190]. Future studies assessing the effect of
psychobiotics upon autistic behaviour in humans will
require a double-blind, placebo-controlled design with
sufficient power.
6 Conclusions and Future Perspectives: A New
Hope?
Through mediators such as the immune system, bacterial
metabolites and the vagus nerve, the gut microbiota reg-
ulate neurophysiological processes from neurotransmis-
sion to cognition and mood. Dysregulation of this
microbiota–gut–brain axis accompanies the neuropathol-
ogy observed in mood and neurodevelopmental disorders,
such as depression, schizophrenia and autism. Preclinical
studies in animal models have provided us with an
understanding into how alterations in the gut microbiota
may contribute towards these neuropsychiatric conditions.
However, greater clinical insight is required to determine
the extent to which these preclinical observations translate
into what is observed in the human condition. Moreover,
it remains to be determined whether these alterations in
the gut microbiota are causal of these neuropsychiatric
conditions (autism in particular) or a comorbid conse-
quence. To paraphrase Yoda (from Star Wars: Episo-
de V—The Empire Strikes Back), ‘‘Much to learn, we still
have’’ regarding the role of the microbiota–gut–brain axis
in neuropsychiatry. Preclinical studies remain vital in
dissecting the mechanism of action of various bacterial
strains upon behaviour. Early clinical data suggest that
psychobiotics could potentially be used as a first-line
treatment for neuropsychiatric conditions. However, this
will require a greater investment in large-scale clinical
trials by food and drug companies to determine whether
psychobiotics have efficacy in conditions such as
depression and autism [191].
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